Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Finasteride effectively improves hair growth and slows hair loss in men with male pattern baldness.

Dutasteride is a safe and effective treatment for hair loss.

The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.

The new gel combining calcipotriene and betamethasone is effective and safe for treating scalp psoriasis.

Bimatoprost is a safe and effective treatment for making eyelashes longer, thicker, and darker.

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.

Promising cancer treatments were found, but the manufacturer closed.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Phage therapy could be a safe and effective new treatment for acne.

Chemoprevention can significantly lower cancer risks and needs more research and collaboration.

Using 5% minoxidil foam twice daily can help regrow hair, especially in younger men aged 20-30.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Tolvaptan can slow kidney disease progression, but doesn't affect mortality or kidney failure.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Significant progress and collaborations in stem cell research and regenerative medicine were made, including advancements in hair growth, cancer therapies, and treatments for neurological disorders.

Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

Rivaroxaban can cause liver injury, allergic reactions, blood vessel inflammation, and hair loss, but these side effects are rare.

Provenge extends prostate cancer survival by about 4 months.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.